Phase I trial of 4-demethoxydaunorubicin
โ
S. Kaplan; C. Sessa; Y. Willems; M. A. Pacciarini; V. Tamassia; F. Cavalli
๐
Article
๐
1984
๐
Springer US
๐
English
โ 454 KB
Twenty-four patients with a variety of solid tumors entered a Phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single oral dose of 10-60 mg/m 2 repeated every 3-4 weeks. Leukopenia was the dose-limiting toxicity. Other toxic effects included mild t